Gilead and Terray Therapeutics Partner to Discover and Develop Small Molecules for Various Targets
Shots:
- Gilead Sciences and Terray Therapeutics have entered into a strategic collaboration for the discovery and development of novel small molecules for various targets
- The alliance will leverage Terray’s tNova platform to discover & develop small molecules for Gilead-selected targets. Gilead gets option to license the compounds and handle further development & commercialization
- Terray will receive an upfront payment, preclinical, clinical & sales milestones plus net-sales based tiered royalties
Ref: Gilead | Image: Terray Therapeutics & Gilead
Related News:- Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
